Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
keep - Dreaming....................
Well gi197845 - Thanks ! My answer is same - I will try to be more patient and more positive regrading INNV, but I don't plan to invest anymore in INNV...... I will just wait and Pray .... Have nice Great Blessed day too !!!
DCTH nice action few days ................
Will see...........................
Its take time , I had same situation with NOK , ALU back to June 2012 & AMD almost one year ago...... look now, they was one step to Bankruptcy .
This is Health product , only ...........
INSIDERS - bought shares 7/3/2017 (Form 4) p.s. look total each beneficial owners
https://ih.advfn.com/p.php?pid=nmona&article=75157822
https://ih.advfn.com/p.php?pid=nmona&article=75157806
https://ih.advfn.com/p.php?pid=nmona&article=75157809
Agree 100% ........
,, Against all hope, Abraham in hope believed,, Romans 4:18
,,Yet he did not waver through unbelief regarding the promise of God, but was strengthened in his faith and gave glory to God,, Romans 4:20 Bible .
I Remember .... (Here is a fact I can tell you about the approval. It will not come after hours. It will come during the day and the stock will halt for 30 minutes while it is occurring. Seen it in many bios awaiting FDA approval. Most do not announce after hours unless they are large companies.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123992810
p.s. Nobody knows what's happening tomorrow !!! But it will....
EMPTY WORDS........................
From the new website yesterday.
An Avalanche of MONEY is coming.
I know that people think I dream a lot, hence my name, but really what I do is my DD and apply common sense. Take this snippet from 5-11-2017 .
According to some sources, Flonase® sales peaked at around $1.3 billion before Clarispray® was introduced as a competitor. Clarispray® has become an important revenue contributor to the Claritinâ„¢ division, which generates nearly $200 million per quarter. With few competitors in the market, Innovus Pharma has a unique opportunity to introduce a third national competing product under the trusted FlutiCareâ„¢ brand name, The Rx form of the API has sold over 177 million prescription units.
Now in the same article this snippet appears:
"The company plans to market the nasal spray through well over 20,000 U.S. retail stores where it is well established as a vendor of record, including Walgreens, CVS, Rite Aid, Kroger, Target, and Safeway. In addition, the company plans to leverage its Beyond Human Sales & Marketing Platform, which has access to ~3,000 newspapers and magazines reaching 20-30 million consumers per month, two million current subscribers, access to over 140 of its websites, online retailers and Amazon."
Now Dr. D says that the will inly sell about $15 million worth in year 1. I ask why so little? I researched as much as I could
and I see that clarispray is sold in the same amount of stores. Without marketing just the fact fluticare will be on the shelf
right next to the big guys will generate more than 15 mill by accident. Being that more people take fluti by prescription than any oyher speay we should prepare for the avalanche of money. Call me what you like, but we will get much more than 15 million in a year and when that happens watch out! p.s. Nice DD from YB .
bid 0.1115c. ask 0.1153c. last 0.1153c. Vol. 400 what are talking about? Level 2 Ameritrade 10.30am
Empty words, empty words , empty words - like usually......
Twist- you time loser with EMPTY WORDS , same like your bro . TRUMP . All yours prediction is FAIL ... its call ,, DOGS BARKING , BUT CARAVAN GOES ,,
TRUMP - voice of LOSER , you said by Friday shares price will be 0.10c. your - words EMPTY !!! Confirmed .....
TRUMP - look you have speech Diarrhea.....
twist - for yes .... for me 41% + UP !!! What are talking about ?
twist- why you bring all time very old information.... its just EMPTY WORDS , EMPTY .... INNV started moving North , are you ready eat your Hat ?
Twist - its my money , not yours !!! I made last summer from INNV $56K + , got shares 0.08-011c. & sold 0.51c. what are you talking about? did same with NOK , and AMD ...... p.s. by the way Yevgeniy - on YB its me ... relax... healthealth - long time ago acc . here
And ,, twist,,- Your NEGATIVITY - step by step eat your Health , but INNV sooner or later going forward.... sorry - & you will be home alone..
Trump - your Word empty like usually ..... ,,DOGS BARKING , BUT CARAVAN GOES,, ....
Nice article Just come in OUT !!!
Innovus Makes Strides Toward Goal of Tripling Revenue in 2017 --
Innovus reported first quarter 2017 revenue of $2.2 million, which is a sharp increase from just $224,000 during the year ago period. On a sequential basis, the company's revenue increased $500,000 -- or 29% -- despite the first quarter traditionally being its weakest. Historically, Innovus Pharmaceuticals quarter per quarter revenues show a very slow first quarter ($224K in 2016), followed by a significant increase in second quarter ($1M or close to 4x increase) and a peak in revenues in its third quarter ($1.9M close to 2x increase) and a slower fourth quarter ($1.7M).
On a linear flat growth basis, the company seems to be tracking to $8.8M in revenue for the year. But if we take into account their historical revenue patterns, the company may be able to reach and exceed its estimates for 2017. During a Q&A session on the earnings conference call, the company indicated that they expect to reach profitability upon hitting a $10 million revenue run rate, and considering past patterns (along with new product introductions and expanded distribution channels for existing products) that figure seems to be reachable this year. Gross margins improved to 79.8% from 46.7% a year ago, while cash used in operations decreased by $500,000 sequentially as the company moves closer to profitability.
"We have not only seen an increase in our net revenue from the most recent fourth quarter 2016 but our operating loss and cash used in operations has improved as we work to achieve our goal of profitability," said Innovus Pharma President & CEO Bassam Damaj. "With the exciting news stemming from the commercial supply agreement we entered into with our new partner for FlutiCareâ„¢ in May 2017 and the recent completion of our registered public equity offering in March 2017, we believe we are well on our way to having the necessary resources to assist us in executing our goals of the expected launch of FlutiCareâ„¢ in the fourth quarter of 2017, the continued expansion of our product lines, and achieving profitability."
https://finance.yahoo.com/news/innovus-makes-strides-toward-goal-130000178.html
Answer to SYD .....Team - here are the responses from Kevin. As I stated before, he is a class-act and a great professional and I have the utmost respect for him.
_____________________________________________________________________________________________
Syd,
Some of this would require divulging information which is not public, but here is what I can tell you.
1) At current growth rate of 29% quarter over quarter Innovus would have revenues in excess of $13 MM. Many of the partnerships and new products were not in place for all of Q1, but will be for the remainder of the year.
2) Agree this is a broad range and hopefully will be clarified in the future.
3) The operating expenses for 2016 were primarily due to the increase in non-cash stock-based compensation to consultants for services rendered and an increase in the amortization of intangible assets as a result of the acquisitions in 2016 and 2015. Many of these are not repeating expenses. Additionally gross margins have jumped dramatically since last year. Your assumptions on revenue necessary to break even and turn profitable may not be correct if you are utilizing all of 2016 as a guide to extrapolate expenses.
4) There are some cash expenses associated with the preparations and launch of Fluticare that were not there in 2016.
Kevin Holmes
Chesapeake Group
From Syd YB.
Here are the questions I sent to Kevin on Saturday w/ CC to Dr. Damaj:
Kevin -
Have a couple of questions which I hope you can answer for me because I left the call on Friday a bit confused.
1) The first disappointment was the $2.2 million in revenue for Q1. Not sure why the revenue was this anemic with all these new Agreements and products on the market.
2) All along for the past 8 months or so the guidance for 2017 has been $15 million in top line revenue. This past Friday, there was no mention of the $15 million guidance. All of a sudden the guidance became "$10 - $15 million."
Why was this downgraded so casually? There is a big difference between $10M and $15M. This is too broad of a range for a small micro-cap company.
3) The CEO or Gutierrez failed to explain what is the path to profitability at the end of 2017? There is no way Innovus can be profitable with a top line revenue of $10 million. If you look at their income statement for year-end 2016, they had $10.6 million in operating expenses alone. How do they plan to reduce these expenses in 2017? They need a minimum of $15 million to have a shot at profitability. There is no path to profitability w/ $10 million in revenue.
4) The CEO had claimed (last year) that INNV had reached cash-flow positive status last summer and ahead of schedule. On Friday the CFO stated that they are striving to be cash-flow positive by the end of 2017. Whose statement is correct?
Sorry Kevin for the straightforward questions and I know you are in a tough spot but would appreciate some clarification on the above questions which are very clear-cut.
Syd-
EMPTY WORDS !!!!
AGREE 100%.....
TRUMP - your prediction price for shares this morning 0.6-07c. is FAILED !!! Its just Confirmed your - EMPTY WORLDS ... no Panic sale , no crash , only few losers scary losers sold . Are you sold ?
SHAWN Team - no sleeping well last night ... early morning you already here with your Negativity.... p.s. The sales number as it still represents tremendous growth (~900% yoy) and it's their record!!! REPEAT !!!I have experience with NOK when I bought $ 1.68C. and sold $8.30 AMD same bought $1.95c. and still keep & NEVER , NEVER , NEVER listen...... ,,investors,, with NEGATIVE EMPTY WORDS !!!
AGREE 100% - with FUTURE
Altheman from YB ...
After sleeping on it a bit, I wanted to share my view on the call. Two words: a) disappointment and b) excitement. What is funny is that these two words will play in hands of both shorts and longs. In terms of disappointment I am not necessarily disappointed with the sales number as it still represents tremendous growth (~900% yoy) and it's their record!!! After all, you will see that prior to earnings I argued that $2.5m would be a strong result for Q1, which would still allow them in my humble view to reach $15m in revenue for 2017. My disappointment was more related to the fact that they continue to over promise and under deliver. You would think that they learned from q4 when they missed $5m full year mark for 2016. Just can't understand why they would do something stupid as this and give guidance of $15m especially given that they already had q1 numbers when they gave guidance. Not really sure that they have a good sales forecasting ability which will be critical for going forward especially when those sales get bigger. I am also disappointed that they continue to shorten the calls and not provide opportunity for all investors to ask "tough" questions. For example, I still don't understand why they issued shares to novalere without getting approval for Fluticare. Second question I wanted to ask is related to their agreement with Hikma. I wanted to confirm that $10-$15m in Fluticare revenue is only related to the agreement with Hikma and that original Anda approval would mean additional revenue. IR confirmed this for me but wanted to hear it from the management. So in general it would have been nice to have opportunity to ask these and many other questions but for some reason management is either ignorant or they are really not interested in answering investors concerns. I guess shareholders meeting will have to do and I will do everything I can to make it to the next one. I do think overall that this management needs to learn how to manage the expectations and learn that their credibility is the most important factor for most long term investors who are investing in this type of early stage company. As far as positives, hard not to be excited about potential here especially related to Fluticare. Let's assume that they get only 5% of market share; that would imply $50m in revenue. I think 5% is a very conservative assumption. For those that have their doubts, question: why would Hikma sign manufacturing agreement with Innovus if they did not think that Fluticare will represent significant enough market share? By signing the agreement Hikma is validating both innovus and Fluticare. In addition it demonstrates ability of this management to think outside the box and reach value add agreements and partnerships. One more thing to note: agreement with Hikma cost them nothing. Finally as far as Fluticare is concerned bashers continue to bring up cost to market this. Guess what? The last equity issue was to be used for the launch. Keep in mind that they already have agreements which would bring them to 20k stores and with their beyond human platform they can reach millions of people without much incremental cost if any. One more thing to note. They currently have $2.5m in cash and if I understood them correctly their cash burn is about $0.5m per quarter. Keep in mind that their goal is to become cash flow positive by year end which then would further reduce need for an additional financing. Point being I don't see much need for additional funding given that any potential increase in costs due to Fluticare launch will be covered by current cash available in addition to cash generation by year end. At the end, I still continue to believe that Fluticare potential is underestimated and only time will show it's true potential. Being one of the three national brands is not insignificant especially in a $1bn+ market. I very much like our chances there. As far as other products, out of 18 products I really think that Vesele will be significant. As you recall, he mentioned during the call that initial results from the trials are coming in. He mentioned that for one reason and one reason only; he knows that results are significant and that this product in combination with Viagra could be blockbuster drug. From my perspective this could have a huge impact on innovus; perhaps even bigger than Fluticare. Thinking long-term; the potential of just these two products is tremendous and again in my humble view completely underestimated. I could make a long-term investment thesis on only these 2 products for which by the way innovus could easily be a buyout target! By the way, let's not forget that innovus has 16 more products on the market!!! Whichever way you look at it, one basically has to decide: are you a short term trader or a long term investor? I continue to believe that long-term investors will be rewarded for their patience and ability to look beyond short term hiccups which many early stage companies experience. I do still feel strongly that management will need to adapt as well and do a better job in managing expectations and listening to it's shareholders. Given above not sure which way share price goes on Monday. I firmly believe that at current levels this is significantly undervalued. I will continue to opportunistically add on any potential weakness.
Confirmed !!! Its Very GOOD !!! Korea just started ship in March !!! 18 product in US, Planning 25 !!! I listened CC.
You crying all time, what are talking about......
SHAWN - So MONDAY , just sale all your position and be FREE . THIS IS FREE COUNTRY - AMERICA !!! p.s. But I don't think you will sale it..... Its very GOOD ER !!!
TRUMP - you so panic person , bad ER only for short players... for long its very GOOD .... - Quarterly Revenue Growth each QUARTER !!!!!! RELAX
TRUMP - its to late save our money , nobody listen to you - Panic man....
TRUMP - with your Luck , yes - you will entering 0.17c. or even 0.70c. negativity bring in your life even MORE NEGATIVITY .....
Message from Syd - YB.
Team - without question, we saw a good step forward yesterday, and as I had suspected a while back, the relationship between Hikma/West-Ward and Dr. Damaj was a natural one. I believe the CEO hedged his bets by entering into this Agreement. While he is confident the original FlutiCare (from Novalere) will be approved before November 2017, he nonetheless, now, through his partnership with Hikma, joins the ranks of GSK and Bayer with a great OTC product for allergic rhinitis and even within this select group, FlutiCare has the slight edge as its compound fluticasone propionate, according to pharmacologists, is equivalent to the Rx form and the best-seller. The reason he hedged his bets is because he did not want to leave anything to chance with respect to his ultimate goal....which is to show profitability at the NOI line item, have positive EPS numbers and up-list ticker symbol "INNV" to NASDAQ. Team that's the CEO's ultimate goal in my opinion.
Getting FlutiCare approved thru the FDA is not his goal. He needed to increase his revenue stream and it makes sense to add a great product to the lineup and generate some needed cash but FlutiCare is not the be-all, end-all. With this new Agreement which commences in the second half of 2017, we can add about $3.5 million to the guidance for 2017 because as the statement said yesterday, Hikma partnership is worth $10 - $15 million for the 12-month period. I am adding a conservative $3.5 million to the original guidance. So essentially this Friday, we should expect the 2017 guidance to be revised to $18.5 million assuming Q1 2017 ended-up being around $3 million.
Dr, Damaj is an experienced and savvy CEO who is focused on improving the SP and shareholder value. This will be a meticulous and a deliberate process that cannot be hurried. For those who will be patient and stay with him through this gradual assent, will be rewarded in a couple of years when INNV is noticed by bigger institutional investors.
Again, I applaud the Agreement signed yesterday and this will serve as another step to making Innovus profitable by the end of 2017 through higher revenues that can offset the operating costs and non-cash derivative liabilities that still need to be flushed-out this year.
500 - trade means price start going UP, 200 - need shares . 300 - badly need shares , MM talking between.....
TRUMP - you WRONG !!! and we will see how you keep your Words . p.s. before your words was guessing and empty.. ...........
no sleep for you until morning My 15....
voice of LOSER TIMES !!!
Trump - your source prediction just guessing - EMPTY WORDS .